As with any patient with hypertriglyceridemia, lipid lowering agents (particularly fibrates) can be of benefit. With regard to PD-specific interventions, it was shown in the IMPENDIA/EDEN trial (JASN 2013) that use of a glucose-sparing PD regimen vs. a standard glucose-based PD regimen can lead to improvements in triglycerides as well as other lipids.